HER2-positive breast cancer: current treatment strategies. - Wikidata - awgldk - TriplyDB

HER2-positive breast cancer: current treatment strategies.

HER2-positive breast cancer: current treatment strategies.

http://www.wikidata.org/entity/Q37201524

about

Inflammatory bowel disease as a model for translating the microbiome Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis Trimodal therapy in squamous cell carcinoma of the esophagus.Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

P2860

Q26853123-6947325F-A79A-4AA5-BC15-49CF804C3FF2 Q33576337-6C21FA32-E407-44B6-8438-F6950C41E719 Q34110523-E77D7D69-69F7-42D0-9FDE-90B0B081E381 Q34129444-70E91DD1-0C71-4178-AB83-8CE6F9CF6DA4 Q35145667-35AB9B7D-E349-4F09-ACB1-3B23A588E4A7 Q36105835-FCE94F17-B5E2-40C9-A14D-084C7E7F21DF Q37160952-2414D395-4ED0-4398-A994-F1A3F0EE4C90 Q39983856-EBAD5143-7BCC-4977-8275-CADA3544935C Q50899665-8925FEB5-4E9C-447E-9AEF-11B13B4A4E64

P2860

HER2-positive breast cancer: current treatment strategies.

http://www.wikidata.org/entity/Q37201524

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HER2-positive breast cancer: current treatment strategies.

@en

HER2-positive breast cancer: current treatment strategies.

@nl

type

label

HER2-positive breast cancer: current treatment strategies.

@en

HER2-positive breast cancer: current treatment strategies.

@nl

prefLabel

HER2-positive breast cancer: current treatment strategies.

@en

HER2-positive breast cancer: current treatment strategies.

@nl

P1433

Q37201524-C7EBBDB6-343F-40E4-9755-6268B0AD634F

P1476

Q37201524-917203E2-959A-49EE-8546-115BC288AF52

P2093

Q37201524-751EE7A5-818D-4FF0-AB7C-FBB9097BA082

Q37201524-A7EAC844-4D70-4379-A571-76987388439D

P2860

Q37201524-04B2FE71-835D-4EA2-811E-501B2AF7B111

Q37201524-090EB77E-7BD9-459F-8226-CDC4E9D0B7BC

Q37201524-20B17AC2-21AE-40D1-938A-EEBEE35DA954

Q37201524-3A101709-D58A-4FA7-809D-3576FA144CA4

Q37201524-4536A501-2DE5-4220-984B-765E508A4BA5

Q37201524-55ECC164-127F-467A-A989-0223449E6D76

Q37201524-5B166487-49DB-48D1-BDE0-0E19F742A449

Q37201524-5C071EA9-D2FE-4D9A-B980-B9D95CC2B1CC

Q37201524-60E602C7-18F0-4A1C-BA70-67F3DBB5D6F5

Q37201524-68BDF3B0-4E3F-4F22-97DF-0F21A136588D

P304

Q37201524-940B05F0-D06A-4766-92E1-D7396778052E

P31

Q37201524-C6CC4400-DF87-4A67-B6C2-6798B4266B8E

P356

Q37201524-D52EDA26-135D-48D9-9136-102403E6E191

P433

Q37201524-23321BC6-E047-4341-8B70-F4026735F46F

P478

Q37201524-0C8D7E6B-0708-47C2-A3F1-DDC2B688BFFE

P577

Q37201524-FCE8F644-CC99-4078-BAF4-093DAF76B931

P698

Q37201524-A8328C64-D20E-47D4-95DE-56D6D64CB018

P356

07357900801971024

P1433

Cancer Investigation

P1476

HER2-positive breast cancer: current treatment strategies.

@en

P2093

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Mansoina Baweja

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Cardiac dysfunction in the trastuzumab clinical trials experience

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer.

Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy.

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

P304

545-552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357900801971024

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18584344

http://www.w3.org/2001/XMLSchema#string